Connor, Clark & Lunn Investment Management (CC&L)’s Enanta Pharmaceuticals ENTA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $112K | Sell |
14,796
-15,669
| -51% | -$118K | ﹤0.01% | 1455 |
|
|
2025
Q1 | $168K | Buy |
30,465
+5,829
| +24% | +$32.2K | ﹤0.01% | 1337 |
|
|
2024
Q4 | $142K | Buy |
24,636
+12,868
| +109% | +$74K | ﹤0.01% | 1351 |
|
|
2024
Q3 | $122K | Buy |
+11,768
| New | +$122K | ﹤0.01% | 1362 |
|
|
2024
Q2 | – | Sell |
-44,629
| Closed | -$779K | – | 1471 |
|
|
2024
Q1 | $779K | Buy |
44,629
+3,264
| +8% | +$57K | ﹤0.01% | 960 |
|
|
2023
Q4 | $389K | Buy |
+41,365
| New | +$389K | ﹤0.01% | 1114 |
|
|
2022
Q4 | – | Sell |
-5,110
| Closed | -$265K | – | 1278 |
|
|
2022
Q3 | $265K | Buy |
+5,110
| New | +$265K | ﹤0.01% | 940 |
|
|
2020
Q3 | – | Sell |
-9,911
| Closed | -$498K | – | 980 |
|
|
2020
Q2 | $498K | Buy |
+9,911
| New | +$498K | ﹤0.01% | 756 |
|
|
2019
Q4 | – | Sell |
-7,950
| Closed | -$478K | – | 968 |
|
|
2019
Q3 | $478K | Buy |
7,950
+5,300
| +200% | +$319K | ﹤0.01% | 693 |
|
|
2019
Q2 | $224K | Buy |
+2,650
| New | +$224K | ﹤0.01% | 883 |
|
|
2019
Q1 | – | Sell |
-3,100
| Closed | -$220K | – | 945 |
|
|
2018
Q4 | $220K | Sell |
3,100
-1,200
| -28% | -$85.2K | ﹤0.01% | 831 |
|
|
2018
Q3 | $367K | Buy |
+4,300
| New | +$367K | ﹤0.01% | 752 |
|
|
2015
Q1 | – | Sell |
-5,300
| Closed | -$270K | – | 585 |
|
|
2014
Q4 | $270K | Sell |
5,300
-4,200
| -44% | -$214K | ﹤0.01% | 477 |
|
|
2014
Q3 | $376K | Buy |
+9,500
| New | +$376K | ﹤0.01% | 424 |
|
|
2014
Q2 | – | Sell |
-10,000
| Closed | -$441K | – | 559 |
|
|
2014
Q1 | $441K | Buy |
+10,000
| New | +$441K | ﹤0.01% | 504 |
|